HC Wainwright Has Negative Outlook of JANX FY2030 Earnings

Key Points

• HC Wainwright lowered its FY2030 EPS estimate for Janux Therapeutics to $0.97 from $1.06, while the current full-year consensus remains a loss of $1.70 per share.
• Janux reported a quarterly loss of $0.35 per share, missing the $0.25 consensus estimate, and revenue of $10.27 million versus expectations of $19.07 million.
• Despite the earnings miss and reduced price targets from several analysts, Janux retains a “Moderate Buy” consensus rating, with an average target price of $37.58 versus a recent share price of $16.41.

Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) - Analysts at HC Wainwright lowered their FY2030 earnings per share (EPS) estimates for shares of Janux Therapeutics in a research report issued to clients and investors on Monday, August 10th. HC Wainwright analyst S. Ramakanth now anticipates that the company will post earnings of $0.97 per share for the year, down from their prior forecast of $1.06. The consensus estimate for Janux Therapeutics' current full-year earnings is ($1.70) per share.

Janux Therapeutics (NASDAQ:JANX - Get Free Report) last announced its quarterly earnings data on Thursday, August 6th. The company reported ($0.35) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.25) by ($0.10). The business had revenue of $10.27 million during the quarter, compared to analyst estimates of $19.07 million.

Several other brokerages also recently issued reports on JANX. Truist Financial reiterated a "buy" rating and issued a $26.00 target price (down from $80.00) on shares of Janux Therapeutics in a research note on Thursday, June 25th. Guggenheim cut their target price on Janux Therapeutics from $58.00 to $55.00 and set a "buy" rating on the stock in a research note on Friday. Wedbush decreased their price target on Janux Therapeutics from $45.00 to $36.00 and set an "outperform" rating for the company in a research note on Friday, May 8th. Stifel Nicolaus set a $35.00 price objective on Janux Therapeutics in a report on Friday. Finally, Piper Sandler lowered their target price on shares of Janux Therapeutics from $30.00 to $26.00 and set an "overweight" rating on the stock in a research note on Friday, May 8th. Nine research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat, Janux Therapeutics has a consensus rating of "Moderate Buy" and an average target price of $37.58.

Janux Therapeutics Price Performance

Shares of Janux Therapeutics stock opened at $16.41 on Tuesday. Janux Therapeutics has a 1 year low of $12.12 and a 1 year high of $35.34. The firm's 50-day moving average is $15.08 and its 200 day moving average is $14.47. The stock has a market cap of $1.00 billion, a price-to-earnings ratio of -10.01 and a beta of 2.50.

Institutional Investors Weigh In On Janux Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of the business. BlackRock Inc. bought a new stake in Janux Therapeutics during the 2nd quarter valued at approximately $94,228,000. State Street Corp lifted its holdings in shares of Janux Therapeutics by 103.8% in the 4th quarter. State Street Corp now owns 3,853,951 shares of the company's stock worth $53,185,000 after acquiring an additional 1,962,486 shares during the last quarter. Prosight Management LP boosted its position in shares of Janux Therapeutics by 176.5% during the fourth quarter. Prosight Management LP now owns 2,392,523 shares of the company's stock valued at $33,017,000 after buying an additional 1,527,173 shares during the period. Wellington Management Group LLP raised its stake in shares of Janux Therapeutics by 129.5% during the fourth quarter. Wellington Management Group LLP now owns 1,610,186 shares of the company's stock valued at $22,221,000 after acquiring an additional 908,582 shares in the last quarter. Finally, Balyasny Asset Management L.P. bought a new stake in Janux Therapeutics during the 4th quarter valued at $12,221,000. 75.39% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other Janux Therapeutics news, insider Janeen Noel Doyle sold 4,059 shares of the company's stock in a transaction that occurred on Tuesday, June 2nd. The shares were sold at an average price of $14.03, for a total value of $56,947.77. Following the completion of the transaction, the insider directly owned 75,941 shares in the company, valued at $1,065,452.23. This represents a 5.07% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 7.90% of the stock is owned by corporate insiders.

Janux Therapeutics Company Profile

Janux Therapeutics is a clinical-stage biotechnology company focused on developing next-generation intratumoral immuno-oncology therapies that harness the body’s innate and adaptive immune systems. The company designs and synthesizes proprietary Toll-like receptor (TLR) agonists to reprogram the tumor microenvironment. Janux is publicly traded on the Nasdaq under the symbol JANX.

Its lead programs include JTX-8064, a fully synthetic TLR4 agonist engineered for optimal stability and potency, and JTX-4014, a TLR1/2 agonist formulated for direct intratumoral administration.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source